PMID: 4956Jan 1, 1976

Long-term hypotensive effect of atenolol (ICI 66.082), a new beta-adrenergic blocking agent

Acta Medica Scandinavica
L HanssonN C Henningsen


A report is given from an on-going multicenter trial in Sweden, in which 117 hypertensive patients have been treated with a new cardioselective beta-adrenergic blocking agent, atenolol (ICI 66.082, Tenormin) for an average of six months (range 2-21). Statistically significant reductions of BP were observed, recumbent by 29/19 mmHg (p less than 0.0001) and standing by 28/18 mmHg (p less than 0.0001). Few and comparatively mild side-effects were seen.


Sep 20, 1973·The American Journal of Cardiology·P Kincaid-Smith
Nov 26, 1966·Lancet·J W Paterson, C T Dollery
May 11, 1974·British Medical Journal·R Felix, F A Ive
Nov 30, 1974·British Medical Journal·J B Cumberbatch
Apr 1, 1972·Klinische Wochenschrift·L HanssonB Hood
Jun 1, 1972·American Heart Journal·F J ZachariasB G Wall
Dec 1, 1971·Acta Medica Scandinavica·L HanssonA Westerlund
Jan 4, 1969·British Medical Journal·B N PRICHARD, P M GILLAM
Sep 19, 1964·British Medical Journal·B N PRICHARD, P M GILLAM


Jan 1, 1979·Acta Medica Scandinavica. Supplementum·K EliassonK Sundqvist
Aug 1, 1981·Circulation·M M Ibrahim, R Mossallam
Jan 1, 1984·Clinical and Experimental Dermatology·D J Gawkrodger, G W Beveridge
Jan 1, 1985·European Journal of Clinical Pharmacology·A Westerlund

Related Concepts

Adrenergic beta-Antagonists
Clinical Trials
Hypertensive Disease

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.